Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Table 2

Results of subgroup analysis of pooled HRs of OS.

Stratified analysis	No. of studies	Pooled HR (95% CI)	value	Heterogeneity
				I^2 (%)	Ph
(1) Cancer type
Gastrointestinal cancer	6	0.55 (0.43–0.68)	<0.001	52.1	0.064
Non-gastrointestinal cancer	7	0.50 (0.37–0.63)	<0.001	63.9	0.011
(2) Cutoff value selection
ROC analysis	9	0.52 (0.41–0.63)	<0.001	62.1	0.007
X-tile software	4	0.52 (0.35–0.69)	<0.001	59.4	0.061
(3) Stage
No metastasis	3	0.56 (0.31–0.81)	<0.001	64.7	0.059
Metastasis	2	0.63 (0.53–0.72)	<0.001	0.0	0.773
Mixed	8	0.48 (0.36–0.60)	<0.001	60.9	0.012
(4) Follow-up time
<5 years	2	0.46 (0.27–0.65)	<0.001	0.0	0.878
≥5 years	11	0.53 (0.43–0.63)	<0.001	64.1	0.002
(5) Analysis modes
Univariate analysis	2	0.73 (0.57–0.88)	<0.001	0.0	0.707
Multivariate analysis	11	0.49 (0.41–0.58)	<0.001	53.6	0.018
(6) Treatments
Mixed	1	0.39 (0.24–0.63)	<0.001	—	—
No surgery	4	0.55 (0.39–0.71)	<0.001	73.1	0.011
With surgery	8	0.53 (0.40–0.65)	<0.001	52.5	0.040